Shanghai Pharmaceutical Expands North; NDRC Price Cuts Impact M&A Targets
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - To accelerate its expansion and strengthen its presence in North China, Shanghai Pharmaceutical Holding Co. in January opened a new representative office in Beijing and established Beijing Shanghai Pharma Aixin Weiye Pharmaceutical Co., to be known as Weiye Pharma, while at the same time announcing the planned acquisition of China Health System
You may also be interested in...
China NT Pharma's Hong Kong IPO Could Trigger Consolidation In Distribution Sector
HONG KONG - China's largest vaccine promotion and sales services provider is expected to go public on the Hong Kong Stock Exchange April 20, which will likely lead to consolidation in China's distribution sector
China NT Pharma's Hong Kong IPO Could Trigger Consolidation In Distribution Sector
HONG KONG - China's largest vaccine promotion and sales services provider is expected to go public on the Hong Kong Stock Exchange April 20, which will likely lead to consolidation in China's distribution sector
China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected
SHANGHAI - China's National Development and Reform Commission has released long-awaited price cuts that will mostly affect multinational pharma companies